Objective To study and evaluate the clinical effects of adjunct!ve immunotherapy with recombinant human IL-2 in a-dults with treatment pulmonary tuberculosis. Method Fifty sputum smear positive treatment TB patients were enrolled into this study. There are 23 cases in intervention group and 25 cases in control group. The chemotherapeutic regime which was 2HRZE/4HR + IL-2 in intervention group and 2HRZE/4HR in control group. Result Forty eight patients completed the treatment course, their outcome were evaluated. Among of them,24 patients from intervention group and 24 patients from control group. The sputum smear conversion, lesion absorbed , cavity shrunk and immune test results in intervention group were better than that of control group. There were no severe side effects among patients received IL-2 for treatment. Conclusion The study suggest that the recombinant IL-2 would be not only a safe biological a-gent.but also an adjunctive immunotherapy for treatment pulmonary tuberculosis, which can facilitate smear, lesion absorbed, immunity of patients with pulmonary tuberculosis.%目的 研究和评价重组人白细胞介素-2(IL-2)辅助治疗肺结核的临床效果.方法 选空洞涂阳初治肺结核50例,观察组25例,采用2HRZE/4HR方案化疗加用白细胞介素-2；对照组25例,采用2HRZE/4HR方案化疗.结果 完成疗程可评价疗效者48例,观察组与对照组各24例,观察组临床症状、痰菌阴转、胸部CT病灶吸收、空洞缩小和闭合以及免疫检测结果均优于对照组.无严重不良反应发生.结论 重组人IL-2有辅助治疗肺结核的作用,可加速结核菌阴转速度,促进病灶吸收.
展开▼
